Drug Trial Radar · NCT03297606
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
720
Planned (sponsor's estimate)
Start
Mar 23, 2018
Primary completion
Dec 31, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- AstraZeneca; Bristol-Myers Squibb; Hoffmann-La Roche; Pfizer; Seagen Inc.
- First posted
- Sep 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.
Conditions
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Advanced Solid Tumors
Interventions
OlaparibDrug
300mg taken twice daily
DasatinibDrug
100mg administered orally once daily
Nivolumab plus IpilimumabDrug
* Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase. * Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.
AxitinibDrug
5mg orally twice daily
BosutinibDrug
500mg orally once daily
CrizotinibDrug
250mg orally twice daily
PalbociclibDrug
125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
SunitinibDrug
50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
TemsirolimusDrug
25mg infused over a 30-60 minute period once a week
ErlotinibDrug
150mg orally, once daily
Trastuzumab plus PertuzumabDrug
Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion. Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.
Vemurafenib plus CobimetinibDrug
Vemurafenib = 960 mg orally every 12 hours. Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest
VismodegibDrug
150mg taken orally, once daily
TucatinibDrug
300mg taken orally, twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate defined as the number of patients with complete response or partial responseTime frame: 4 years
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Cross Cancer Institute
Edmonton, Alberta, Canada · Recruiting
BCCA - Kelowna
Kelowna, British Columbia, Canada · Recruiting
BCCA - Vancouver
Vancouver, British Columbia, Canada · Recruiting
Kingston Health Sciences Centre
Kingston, Ontario, Canada · Recruiting
London Health Sciences Centre Research Inc.
London, Ontario, Canada · Recruiting
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada · Recruiting
University Health Network
Toronto, Ontario, Canada · Recruiting
The Jewish General Hospital
Montreal, Quebec, Canada · Recruiting
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada · Recruiting
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.